Biotide Peptides Separates Blood Changes From Health Gains

This site shows where the proof stops

Drug makers designed CJC-1295 and Ipamorelin to change growth hormone in different ways, and this site helps you keep the pair, CJC-1295 alone, and Ipamorelin alone straight. You can see what happened in people, animals, or dish-grown cells. The site doesn't provide your care or sell you a service.

The proof is uneven. Small human blood tests found hormone changes. Animal and cell work fills much of the record. One Phase 2 trial—an early human test for benefit and short-term harm—failed its main goal. Reports from users reach far beyond those facts.

CJC-1295 with Ipamorelin appears first because the drugs are often discussed together. Two different hormone messages may explain why they are paired. The set blend still lacks a fair test in people. You can compare the drugs, then bring your health questions to your own doctor.

Each finding stays with the test that found it

A small number in brackets leads to the references page. There you can see the paper, its writers, its year, and a link. That short note tells you which paper supports the claim.

A result also stays with the people or animals that were tested. If healthy adults received 30 micrograms for each kilogram of body weight under the skin, the page says so. The figure doesn't become a plan for you. Work in animals, dish-grown cells, or a related drug is named plainly for you.

Missing proof stays visible too. The fixed pair has no fair trial. A Phase 2 trial—an early human check—failed its main test. Long human safety work is absent. The comparison page helps you stop one drug's finding from sliding over to another.

The site can't treat you, set a dose, or find a seller

Biotide Peptides sells nothing, treats no one, and gives no medical advice. It won't supply, find, or arrange a peptide. No seller pays for a mention or referral. No one here can diagnose you, write a prescription, or give an amount, timing, or way to take a drug. An animal amount never becomes advice for a person.

These are research drugs, not approved medicine. WADA, the world sport drug-testing body, bans all three. Pharmacy-mixing rules changed in 2024. CJC-1295 and Ipamorelin left Category 2, FDA's temporary list for raw ingredients proposed for pharmacy mixing. A later 2024 meeting of the group that advises FDA didn't back either drug for mixing. Leaving the temporary list wasn't an approval. A licensed doctor can discuss approved care for your health.